Loading
Hepatocellular Carcinoma Treatment and Prognosis · Journal article
Frontiers in Pharmacology · September 7, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing the pathophysiology of systemic therapy-related liver injury in HBV-associated HCC and proposing a structured management framework encompassing pretreatment risk assessment, prophylaxis, monitoring, and severity-based intervention. The review identifies knowledge gaps including the need for predictive biomarkers and personalized risk stratification, but presents no new empirical evidence and does not quantify the magnitude of risk or benefit of the proposed interventions.
Journal article. Patients with HBV-associated hepatocellular carcinoma receiving systemic therapy.
Treatment-induced liver injury in HBV-related HCC patients with pre-existing inflammation, fibrosis, and cirrhosis raises risks of treatment interruption, impaired efficacy, and acute liver failure Liver injury mechanisms include direct cytotoxicity, immune-mediated hepatitis, vascular damage, and HBV reactivation Systemic therapies (TKIs, ICIs, ICI-antiangiogenic combinations) have revolutionized advanced HCC treatment but carry hepatotoxic risk
Efficacy or safety of proposed management interventions (prophylaxis, monitoring schedules, severity-based protocols) not demonstrated Liver injury mechanisms include direct cytotoxicity, immune-mediated hepatitis, vascular damage, and HBV reactivation
Clinicians managing HBV-associated HCC on systemic therapies should adopt a structured approach incorporating pretreatment risk assessment, prophylaxis, monitoring, differential diagnosis, and multidisciplinary decision-making to preserve liver function. However, the framework is consensus-based rather than empirically validated, and specific intervention efficacy is not quantified.
A structured narrative review synthesizing pathophysiological mechanisms, drug hepatotoxicity profiles, and a proposed clinical management framework for treatment-related liver injury in HBV-associated HCC, intended to guide clinical decision-making.
Clinicians managing HBV-associated HCC on systemic therapies should adopt a structured approach incorporating pretreatment risk assessment, prophylaxis, monitoring, differential diagnosis, and multidisciplinary decision-making to preserve liver function. However, the framework is consensus-based rather than empirically validated, and specific intervention efficacy is not quantified.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally, with chronic hepatitis B virus (HBV) infection as the predominant risk factor. Systemic therapies including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and ICI-antiangiogenic combinations have revolutionized advanced HCC treatment. However, treatment-induced liver injury is a major concern, especially in HBV-related HCC patients with pre-existing inflammation, fibrosis, and cirrhosis, which raises risks of treatment interruption, impaired efficacy, and acute liver failure. Liver injury arises from direct cytotoxicity, immune-mediated hepatitis, vascular damage, and HBV reactivation. This review summarizes the pathophysiological mechanisms of treatment-related liver injury in HBV-related HCC, analyzes the hepatotoxic profiles of tyrosine kinase inhibitors, immune checkpoint inhibitors, combination regimens and emerging agents, and proposes a structured clinical management framework including pretreatment risk assessment, prophylaxis, monitoring, differential diagnosis and severity-based interventions supported by multidisciplinary care. It aims to offer evidence-based guidance for clinicians to preserve liver function while safely administering effective antitumor therapy. The review also highlights key knowledge gaps and future research directions, including predictive biomarkers, personalized risk stratification and proactive safety evaluation of new drugs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.